Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acute myeloid leukemia in children and adolescents: identification of new molecular targets brings promise of new therapies.

Hematology. American Society of Hematology. Education Program - 1 Jan 2015

Kolb E Anders, Meshinchi Soheil

Abstract excerpt

Recent reports of recurrent mutations in childhood acute myeloid leukemia (AML) have identified potential targets for new therapeutic strategies. Acute promyelocytic leukemia (APL) is characterized commonly by a fusion between the PML gene and the RARA gene, genes targetable by arsenic (ATO) and retinoic acid (ATRA), respectively. A mutation in GATA1, common in AML of Down syndrome (ML-DS), renders cells more...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Arsenic Trioxide
Share to Arsenicals
Share to Down Syndrome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to GATA1 Transcription Factor

Share to Leukemia, Promyelocytic, Acute

Share to Medical Oncology

Share to Oxides

Share to Tretinoin

Source

Identifiers

PMID: 26637766
DOI: 10.1182/asheducation-2015.1.507

Genes

FLT3
GATA1
KIT
PML
RARA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Acute myeloid leukemia in children and adolescents: identification of new molecular targets brings promise of new therapies.PMID 26637766Read ↗

Molecular-Targeted Therapy of Pediatric Acute Myeloid Leukemia.Semantic proximity Read ↗

Harnessing the potential of epigenetic therapies for childhood acute myeloid leukemia.Semantic proximity Read ↗

Pharmacogenomic Profiling of Pediatric Acute Myeloid Leukemia to Identify Therapeutic Vulnerabilities and Inform Functional Precision MedicineSemantic proximity Read ↗

Unique clinical and biological features of leukemia in Down syndrome children.Semantic proximity Read ↗

New agents for the treatment of acute myeloid leukemia.Semantic proximity Read ↗

Pediatric Acute Myeloid Leukemia (AML): From Genes to Models Toward Targeted Therapeutic InterventionSemantic proximity Read ↗

DLK1 is a GATA1s-Driven Dependency and Therapeutic Target in Down Syndrome-Associated Myeloid LeukemiaSemantic proximity Read ↗

Towards precision medicine in childhood leukemia--insights from mutationally activated cytokine receptor pathways in acute lymphoblastic leukemia.Semantic proximity Read ↗

Epigenetic targets in hematopoietic malignancies.Semantic proximity Read ↗

Genome-wide CRISPR/Cas9 screen identifies AraC-daunorubicin-etoposide response modulators associated with outcomes in pediatric AMLSemantic proximity Read ↗

High GATA2 expression is a poor prognostic marker in pediatric acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.